F13.982
BillableSedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is F13.982 an HCC code?
Yes. F13.982 maps to Drug Use Disorder/Substance Use Disorder, Moderate/Severe under the CMS-HCC V28 risk adjustment model (and Drug/Alcohol Dependence under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for F13.982
For F13.982 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed F13.982 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
F13.982 is the ICD-10-CM diagnosis code for sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder. A person uses sedative, hypnotic, or anti-anxiety medications without a diagnosed substance use disorder and develops sleep problems as a result of using these drugs. F13.982 sits in the ICD-10-CM chapter for mental, behavioral and neurodevelopmental disorders (f01-f99), within the section covering mental and behavioral disorders due to psychoactive substance use (f10-f19).
Under the CMS-HCC V28 risk adjustment model, F13.982 maps to Drug Use Disorder/Substance Use Disorder, Moderate/Severe (HCC 137) with a community, non-dual, aged base RAF weight of 0.358. Under the older CMS-HCC V24 model, F13.982 maps to Drug/Alcohol Dependence (HCC 55) with a community, non-dual, aged base RAF weight of 0.334. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Document the specific sleep disturbance (insomnia, hypersomnia, etc.) if possible, though this code captures unspecified sleep disorder. Because F13.982 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for F13.982 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Document the specific sleep disturbance (insomnia, hypersomnia, etc.) if possible, though this code captures unspecified sleep disorder
- •Distinguish between sleep disorders caused by the medication versus pre-existing sleep conditions that may have prompted the medication use
Clinical Significance
Sleep disorder induced by unspecified sedative use is a paradoxical complication where sleep-promoting medications disrupt normal sleep architecture. This is particularly common with chronic benzodiazepine and nonbenzodiazepine hypnotic use. The unspecified use status indicates the provider has not classified the use pattern, but the clinical significance of the induced sleep disorder remains important for treatment decisions.
Documentation Requirements
- ✓Documentation of sedative, hypnotic, or anxiolytic use
- ✓Specific sleep disturbance type (insomnia, hypersomnia, parasomnia)
- ✓Provider attribution of sleep disorder to the substance
- ✓Differentiation from rebound insomnia during withdrawal
- ✓Sleep assessment findings or study results if available
- ✓Impact on daytime functioning
Commonly Confused Codes
- •F13.182 — Sedative ABUSE with induced sleep disorder; when abuse is confirmed
- •F13.282 — Sedative DEPENDENCE with induced sleep disorder; when dependence is confirmed
- •G47.00 — Insomnia, unspecified; primary sleep disorder
- •G47.10 — Hypersomnolence, unspecified; primary sleep disorder
- •F13.930 — Unspecified use with withdrawal uncomplicated; withdrawal insomnia differs from induced sleep disorder